Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 4/2017

01-08-2017 | Case Report

Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia

Authors: Kana Daijo, Tomokazu Kawaoka, Takashi Nakahara, Yuko Nagaoki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Keiichi Hara, Go Tajima, Masao Kobayashi, Kazuaki Chayama

Published in: Clinical Journal of Gastroenterology | Issue 4/2017

Login to get access

Abstract

The urea cycle converts ammonia and produces urea. One form of urea cycle abnormality is ornithine transcarbamylase (OTC) deficiency. This hereditary disorder is associated with hyperammonemia. OTC deficiency commonly appears during neonatal and early childhood life and is rare in adults. We report a 69-year-old man who presented at the local hospital with 3-day loss of appetite, early morning vomiting, and state of confusion. Blood ammonia was 293 μg/dl. At 2–3 h after admission, the patient went into a deep coma. He was intubated and admitted immediately to the intensive care unit. Treatment, including sustained hemodialysis, failed to lower blood ammonia level. His grandchild died of OTC deficiency at 6 year of age. Computed tomography, magnetic resonance imaging and esophagogastroduodenoscopy showed no abnormalities. On admission to our hospital, he complained of vomiting and disturbance of consciousness, hyperammonemia, and normal anion gap. Genetic analysis showed A208T mutation. The deceased grandchild with OTC deficiency also had the same mutation. Long-term hemodialysis coupled with administration of l-arginine and lactulose resulted in improvement of blood ammonia level. Early diagnosis and treatment of adult-onset OTC deficiency are essential to avoid serious complications.
Literature
1.
go back to reference Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012;35:777–85.CrossRefPubMed Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012;35:777–85.CrossRefPubMed
2.
go back to reference Lichter-Konecki U, Caldovic L, Morizono H, et al. Ornithine transcarbamylase deficiency. In: Gene reviews (R). Seattle: University of Washington; 1993. Lichter-Konecki U, Caldovic L, Morizono H, et al. Ornithine transcarbamylase deficiency. In: Gene reviews (R). Seattle: University of Washington; 1993.
3.
go back to reference Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996;335:855–9.CrossRefPubMed Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996;335:855–9.CrossRefPubMed
4.
go back to reference Matsuda I, Matsuura T, Nishiyori A, et al. Phenotypic variability in male patients carrying the mutant ornithine transcarbamylase (OTC) allele, Arg40His, ranging from a child with an unfavourable prognosis to an asymptomatic older adult. J Med Genet. 1996;33:645–8.CrossRefPubMedPubMedCentral Matsuda I, Matsuura T, Nishiyori A, et al. Phenotypic variability in male patients carrying the mutant ornithine transcarbamylase (OTC) allele, Arg40His, ranging from a child with an unfavourable prognosis to an asymptomatic older adult. J Med Genet. 1996;33:645–8.CrossRefPubMedPubMedCentral
5.
go back to reference Nishiyori A, Yoshino M, Tananari Y, et al. Y55D mutation in ornithine transcarbamylase associated with late-onset hyperammonemia in a male. Hum Mutat. 1998;(Suppl 1):S131–3. Nishiyori A, Yoshino M, Tananari Y, et al. Y55D mutation in ornithine transcarbamylase associated with late-onset hyperammonemia in a male. Hum Mutat. 1998;(Suppl 1):S131–3.
6.
go back to reference Klein OD, Kostiner DR, Weisiger K, et al. Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male. Hepatol Int. 2008;2:390–4.CrossRefPubMedPubMedCentral Klein OD, Kostiner DR, Weisiger K, et al. Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male. Hepatol Int. 2008;2:390–4.CrossRefPubMedPubMedCentral
7.
go back to reference Bijvoet GP, van der Sijs-Bos CJ, Wielders JP, et al. Fatal hyperammonaemia due to late-onset ornithine transcarbamylase deficiency. Neth J Med. 2016;74:36–9.PubMed Bijvoet GP, van der Sijs-Bos CJ, Wielders JP, et al. Fatal hyperammonaemia due to late-onset ornithine transcarbamylase deficiency. Neth J Med. 2016;74:36–9.PubMed
8.
go back to reference Ausems MG, Bakker E, Berger R, et al. Asymptomatic and late-onset ornithine transcarbamylase deficiency caused by a A208T mutation: clinical, biochemical and DNA analyses in a four-generation family. Am J Med Genet. 1997;68:236–9.CrossRefPubMed Ausems MG, Bakker E, Berger R, et al. Asymptomatic and late-onset ornithine transcarbamylase deficiency caused by a A208T mutation: clinical, biochemical and DNA analyses in a four-generation family. Am J Med Genet. 1997;68:236–9.CrossRefPubMed
9.
go back to reference Yamaguchi S, Brailey LL, Morizono H, et al. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat. 2006;27:626–32.CrossRefPubMed Yamaguchi S, Brailey LL, Morizono H, et al. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat. 2006;27:626–32.CrossRefPubMed
10.
go back to reference Morioka D, Kasahara M, Takada Y, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transplant. 2005;11:1332–42.CrossRef Morioka D, Kasahara M, Takada Y, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transplant. 2005;11:1332–42.CrossRef
Metadata
Title
Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia
Authors
Kana Daijo
Tomokazu Kawaoka
Takashi Nakahara
Yuko Nagaoki
Masataka Tsuge
Akira Hiramatsu
Michio Imamura
Yoshiiku Kawakami
Hiroshi Aikata
Keiichi Hara
Go Tajima
Masao Kobayashi
Kazuaki Chayama
Publication date
01-08-2017
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 4/2017
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-017-0753-0

Other articles of this Issue 4/2017

Clinical Journal of Gastroenterology 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine